Israel - engelsk - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - pemetrexed as disodium hemipentahydrate - powder for concentrate for solution for infusion - pemetrexed as disodium hemipentahydrate 500 mg - pemetrexed - pemetrexed s.k. in combination with cisplatin is indicated for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curatible surgery. pemetrexed s.k. in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed s.k. is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed s.k. is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.

Irland - engelsk - HPRA (Health Products Regulatory Authority)

ever valinject gmbh - pemetrexed - concentrate for solution for infusion - 25 milligram(s)/millilitre - pemetrexed

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 1102.8 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 551.4 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - pemetrexed disodium, quantity: 110.28 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma pemetrexed sun, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer pemetrexed sun in combination with cisplatin is indicated for initial treatment of patients with locally advance or metastatic non-small cell lung cancer other than predominantly squamous cell histology. pemetrexed sun as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - pemetrexed disodium hemipentahydrate, quantity: 604 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: mannitol; hydrochloric acid; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer (nsclc),pemetrexed, in combination with cisplatin, is indicated for initial treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology.,pemetrexed, as monotherapy, is indicated for the treatment of patients with locally advanced or metastatic nsclc other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Malta - engelsk - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 100 mg - antineoplastic agents

Malta - engelsk - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - pemetrexed - powder for concentrate for solution for infusion - pemetrexed 500 mg - antineoplastic agents

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 110.29 mg (equivalent: pemetrexed, qty 100 mg) - injection, powder for - excipient ingredients: mannitol; sodium hydroxide; hydrochloric acid - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - pemetrexed disodium, quantity: 1102.9 mg (equivalent: pemetrexed, qty 1000 mg) - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; sodium hydroxide - malignant pleural mesothelioma,pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,non-small cell lung cancer,pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.